SMi is delighted to announce its 13th annual Clinical Trials in CNS Conference. With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society. With this comes the need for new and improved therapies for treating neurodegenerative conditions. From Alzheimer's to Parkinson's disease, the target and mechanism by which a disease manifests itself presents unique challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.
This conference will give delegates the opportunity to gain additional insights into the best practices in clinical trials, as well as address the challenges in CNS research and by looking at the latest pre-clinical and clinical studies.
This is an opportunity not to be missed, as we delve into the complex and exciting world of Central Nervous System discovery, allowing delegates to learn, explore and debate the key areas of CNS, its preclinical discovery and its clinical trials.
Reasons to Attend:
• Understand the recent failures in CNS development and how translation did not work
• Examine the multi-stakeholder approach to self-management and multidisciplinary care in patients with MS
• Discuss the past, present and future of CNS medicines research
• Analyse novel biomarkers for the brain
• Review the collaboration between industry and academic partnering
Tine Bryan Stensbøl, Divisional Director Discovery Pharmacology Research, Lundbeck
Alan Palmer, Co-Founder and Director, MS Therapeutics
Veronique Bragulat, Clinical Imaging Manager, GSK
Sophie Dix, Senior Research Scientist, Neurodegenerative Disease Drug Hunting Team, Eli Lilly
David Willé, Applied Statistician, GSK
Peter Joseph Jongen, Founding Director, MS4 Research Institute
Ernst-Wilhelm Radue, CEO, MIAC AG
Edwin Johnson, Director, Stockholm Brain Institute
Shahid Zaman, Affiliated Lecturer, University of Cambridge